<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110172</url>
  </required_header>
  <id_info>
    <org_study_id>I84412001</org_study_id>
    <nct_id>NCT03110172</nct_id>
  </id_info>
  <brief_title>Short-term Efficacy of Antidepressant in Patients Underwent TKA</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalian Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dalian Municipal Central Hospital</source>
  <brief_summary>
    <textblock>
      By taking certain antidepressant in early postoperative period，which is supposed to improve
      the psychological status of patients with osteoarthritis, explore the effect of certain
      antidepressant on the recovery of the early stage after the operation of knee joint
      replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators are going to investigate the efficacy of Duloxetine on pain,
      physical function, mental health and quality of life in patients underwent TKAs.

      The control group is going to be given celecoxib 200mg/24h to 2 weeks after operation.On the
      basis of the above scheme, the treatment group is going to receiving duloxetine 60mg/24h to 8
      weeks after operation.HAMD-17 scale, KSS scale, SF-36 scale and WOMAC scale will be used to
      evaluate the two groups before and after operation for 4 and 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patients will be randomly divided into two groups. The control group is going to be given celecoxib 200mg/24h to 2 weeks after operation. On the basis of the above scheme, the The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score of participants with Duloxetine as assessed by Western Ontario and McMaster Universities Index after 4 weeks of treatment.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>A face-to-face questionnaire will be conducted by two trained interviewers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Function score of participants with Duloxetine as assessed by Knee Society Score after 4 weeks of treatment.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>A face-to-face questionnaire will be conducted by two trained interviewers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score of participants with Duloxetine as assessed by Western Ontario and McMaster Universities Index after 8 weeks of treatment.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>A face-to-face questionnaire will be conducted by two trained interviewers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function score of participants with Duloxetine as assessed by Knee Society Score after 8 weeks of treatment.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>A face-to-face questionnaire will be conducted by two trained interviewers</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Osteoarthritis Of Knee</condition>
  <arm_group>
    <arm_group_label>KSS scale</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Knee Society Score with Duloxetine Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAMD-17 scale</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hamilton Depression Score with Duloxetine Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SF-36 scale</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WOMAC scale</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine Hydrochloride</intervention_name>
    <description>The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation</description>
    <arm_group_label>KSS scale</arm_group_label>
    <arm_group_label>HAMD-17 scale</arm_group_label>
    <arm_group_label>SF-36 scale</arm_group_label>
    <arm_group_label>WOMAC scale</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No extra articular malformations are diagnosed and accord with Kellgren-Lawrence
             criteria

          2. Primary TKA surgery,Varus is smaller than 20°

          3. Always there is no history of mental illness, no history of relevant medicine

          4. Be able to read and understand Chinese, with good communication skills

          5. Voluntary participation in this clinical study

        Exclusion Criteria:

          1. Previous history of mental and psychological illness

          2. With severe diseases in respiratory system, circulatory system or digestive system

          3. Allergic to duloxetine and celecoxib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QI Zhiming, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dalian Municipal Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dalian municipal central hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dalian Municipal Central Hospital</investigator_affiliation>
    <investigator_full_name>Zhu Bin</investigator_full_name>
    <investigator_title>Principal Investigator，Graduate Student</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Depression</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

